OR WAIT null SECS
PharmaLex has announced the launch of a new service line, Biopharma Excellence, and appointed a new Chief Medical Officer.
PharmaLex Group (Frankfurt, Germany) has announced the launch of a new service line, Biopharma Excellence, and the appointment of ex-MHRA scientific lead Dr. Christian K. Schneider as head of the new unit and as its Chief Medical Officer.
Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence, under the PharmaLex brand. Its launch comes as the maturation of the biopharma industry accelerates, giving commercial form to important new innovation in fields including cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars. It serves biopharmaceutical companies, ranging from small startups to divisions of large, established global life sciences organizations. Its global, multi-disciplinary solutions are geared to commercial as well as scientific and regulatory success, efficiently delivering new life-saving treatments to patients.
Christian Schneider is a medical doctor by training. He joined the UK’s MRHA in 2016 (initially as Director of National Institute for Biological Standards and Control, before assuming the interim position of Chief Scientific Officer), and he was Medical Head of the Division for Medicines Licensing and Availability at the Danish Medicines Agency. At the European Medicines Agency (EMA), he held various positions including member of the Committee for Medicinal Products for Human Use (CHMP), Chair of the Biosimilar Medicinal Products Working Party, and member of the Scientific Advice Working Party.
Of his move to Biopharma Excellence, Christian commented: “I am deeply passionate about biological medicines and, after a career in leading roles at major regulatory agencies, I wanted to put my expertise to use in helping next generations of drug developers bring their innovations to market.”